Zymo defends US antitrust counterclaims in Qiagen's patent suit
MLex Summary: Zymo Research opposed Qiagen motion to dismiss amended US antitrust counterclaims in a patent suit over technology that allows researchers to extract nucleic acids. “It is unsurprising that Qiagen...To view the full article, register now.
Already a subscriber? Click here to view full article